Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates
Oculis Reports Q1 2026 Financial Results and Provides Company Update
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
Lumentum Q3 Earnings Loom: Buy or Sell the Stock Ahead of Results?
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Oculis Publishes Invitation to the Annual General Meeting
Oculis Publishes Invitation to the Annual General Meeting
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Oculis to Participate in Upcoming Investor Conferences
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Lumentum Surges with S&P 500 Inclusion and NVIDIA Partnership
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Oculis to Participate in Upcoming Investor Conferences
Oculis to Participate in Upcoming Investor Conferences
Oculis Publishes 2025 Consolidated Financial Statements
Brokerages Set Oculis Holding AG (NASDAQ:OCS) Target Price at $41.50
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
Oculis Appoints Katie Kazem as Chief Legal Officer
Oculis Appoints Katie Kazem as Chief Legal Officer
Oculis Holding AG (OCS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Brokerages Set Oculis Holding AG (NASDAQ:OCS) Target Price at $41.50
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
Oculis tilkynnir um að Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hafi veitt Privosegtor stöðu byltingarkennds meðferðarlyfs til meðhöndlunar á sjóntaugabólgu
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Wall Street Analysts Predict a 106.04% Upside in Oculis Holding AG (OCS): Here's What You Should Know
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities